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Aims On the basis of the JUPITER trial, European health authorities recently approved the use of rosuvastatin to reduce
ﬁrst major cardiovascular events among ‘high’ global risk primary prevention patients deﬁned either by Framingham
risk score .20% or European systematic coronary risk evaluation (SCORE) ≥5%. However, as these are post hoc
analyses, data describing these subgroups have not previously been available to the clinical community.
Methods
and results
We randomized 17 802 apparently healthy men aged ≥50 and women ≥60 with low-density lipoprotein cholesterol
(LDL-C) ,3.4 mmol/L, who were at an increased vascular risk due to elevated levels of C-reactive protein measured
withahigh-sensitivity(hs)assaytorosuvastatin20 mgdailyorplacebo.Patientswithhighglobalcardiovascularriskatbase-
line were identiﬁed by 10-year Framingham risk score .20% or SCORE risk ≥5%. During 1.8-year median follow-up
(maximum 5 years) of patients with Framingham risk .20%, the rate of myocardial infarction/stroke/cardiovascular
death was 9.4 and 18.2 per 1000 person-years in rosuvastatin and placebo-allocated patients, respectively [hazard ratio
(HR):0.50,95% conﬁdence interval(CI):0.27–0.93,P ¼ 0.028].Among patients withSCORErisk ≥5%,thecorrespond-
ing rates were 6.9 and 12.0 using a model extrapolating risk for age ≥65 years (HR: 0.57, 95% CI: 0.43–0.78, P ¼ 0.0003)
and rates were 5.9 and 12.7 when risk for age was capped at 65 years (HR: 0.47, 95% CI: 0.32–0.68, P , 0.0001).
Conclusion In primary prevention patients with elevated hs C-reactive protein who have high global cardiovascular risk (10-year
Framingham risk score .20% or SCORE risk ≥5%), but LDL-C levels not requiring pharmacologic treatment,
rosuvastatin 20 mg signiﬁcantly reduced major cardiovascular events.
ClinicalTrial.gov Identiﬁer: NCT00239681
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Introduction
The Justiﬁcation for Use of statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial was designed to
investigate whether rosuvastatin decreased ﬁrst major cardiovascu-
lar events among patients with levels of low-density lipoprotein
cholesterol (LDL-C) ,3.4 mmol/L (130 mg/dL), but who were
at increased cardiovascular risk due to elevated levels of
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1 As previously reported,
after median follow-up of 1.9 years (maximum 5 years), rosuvasta-
tin use was associated with a 54% reduction in myocardial infarc-
tion (MI), a 48% reduction in stroke, a 46% reduction in
revascularization, a 43% reduction in venous thromboembolism,
and a 20% reduction in total mortality.
1,2 On this basis, the
United States Food and Drug Administration approved the use
of rosuvastatin for primary prevention of cardiovascular events
among JUPITER eligible participants with elevated hs C-reactive
protein and at least one additional risk factor.
3 In contrast, the
Dutch Medical Agency (the MEB) and 18 other European health
authorities have approved rosuvastatin for the subgroup of trial
participants who were considered to be at ‘high risk’ either on
the basis of an estimated 10-year Framingham risk score .20%
or an estimated systematic coronary risk evaluation (SCORE)
risk of ≥5%.
4 As neither of these criteria were used in the
design of the JUPITER trial, these post hoc data, not published pre-
viously, are likely to be of utility for European practitioners and are
thus presented here.
Methods
JUPITER was a double-blind, placebo-controlled trial which random-
ized apparently healthy men aged ≥50 and women aged ≥60, with
LDL-C ,3.4 mmol/L (130 mg/dL) and C-reactive protein ≥2 mg/L in
26 countries. Participants did not qualify for statin therapy according
to guidelines in effect in 2003, but were at increased cardiovascular
risk due to evidence of systemic inﬂammation.
5
Full details of the trial protocol, procedures, and methods of con-
ﬁrming clinical endpoints and ascertaining adverse events have been
presented previously.
1,6 Trial exclusion criteria included use within 6
weeks before screening of any lipid-lowering therapies, the current
use of post-menopausal hormone replacement therapy, evidence of
hepatic dysfunction, serum creatinine .177 mmol/L, diabetes mellitus,
prior cardiovascular or cerebrovascular events, chronic inﬂammatory
conditions such as severe arthritis, lupus, or inﬂammatory bowel
disease, or other serious medical conditions that might compromise
safety or successful completion of the study.
Potentially eligible subjects underwent a 4-week placebo run-in
phase; those with compliance .80% were randomly allocated to rosu-
vastatin 20 mg daily or placebo and followed for occurrence of the
primary endpoint, a composite of MI, stroke, arterial revascularization,
unstable angina, or conﬁrmed death from cardiovascular causes. An
independent endpoint committee adjudicated primary endpoint
events. Evaluation of all-cause mortality, MI/stroke/cardiovascular
death, fatal/non-fatal MI, and fatal/non-fatal stroke was pre-speciﬁed.
The trial’s monitoring plan called for two interim efﬁcacy analyses
with the O’Brien–Fleming stopping boundaries determined by
means of the Lan–DeMets approach. The stopping boundary was
crossed at the ﬁrst planned efﬁcacy evaluation, and on 29 March
2008, the independent data and safety monitoring board
recommended termination of the trial. The steering committee
accepted that recommendation and only major cardiovascular events
occurring prior to 30 March 2008 are included in this analysis.
Reporting of adverse events and all-cause mortality continued in a
blinded manner until each participant appeared for a closeout visit
and discontinued study medication.
Clinic physicians reported adverse events as verbatim terms, which
were coded to Medical Dictionary for Regulatory Activities (MedDRA)
preferred terms
7 by an automated system, over-read by trained
coders. We report here treatment-emergent adverse events, i.e.
events that either began or worsened after randomization.
Participants provided fasting blood samples for lipid proﬁles at base-
line, annually thereafter, and at the ﬁnal visit. Alanine aminotransferase
was measured at baseline, 3 and 6 months after randomization, semi-
annually thereafter, and at the ﬁnal visit. Serum creatinine was
measured at baseline, 1 year after randomization, and at the ﬁnal
visit. We estimated glomerular ﬁltration rate by the Modiﬁcation of
Diet in Renal Disease study equation.
8
Statistical analyses
For consistency with post hoc analyses performed for the European
health authorities, all study participants were classiﬁed according to
10-year global risk estimates using the Framingham risk score
9 and
the European SCORE risk algorithm.
10 The Framingham risk score esti-
mates the 10-year risk of MI/coronary death on the basis of age,
gender, smoking status, blood pressure, and total and high-density lipo-
protein cholesterol (HDL-C), whereas the SCORE algorithm estimates
the global 10-year risk of cardiovascular death on the basis of age,
gender, smoking status, systolic blood pressure, total cholesterol,
and geographic region. The regional risk was based on each partici-
pant’s country of enrolment; those enrolled in Belgium, Canada,
Chile, Israel, Mexico, the Netherlands, and Switzerland were
categorized as low risk. Patients enrolled in Argentina, Brazil, Bulgaria,
Colombia, Costa Rica, Denmark, El Salvador, Estonia, Germany,
Norway, Panama, Poland, Romania, Russia, South Africa, UK, USA,
Uruguay, and Venezuela were categorized as high risk.
The SCORE model is limited to ages 45–64 years. To account for
the large proportion of subjects enrolled in JUPITER older than 65
years (n ¼ 10 237), a modiﬁcation of the SCORE model was used in
which the risk conferred by age was extrapolated for patients aged
65 or older (extrapolated model). Extrapolation was based on the
contribution of age to the risk of cardiovascular death as assessed in
the algorithm for patients up to 65 years of age. The extrapolated
model is the model cited in the European CRESTOR Summary of
the Product Characteristics.
4 An analysis was also performed using
the SCORE algorithm capped at 65 years (capped model), in which
all subjects 65 years or older were assigned the risk of a 64-year
old. This more conservative approach resulted in fewer patients
being classiﬁed as high risk; 52% of the JUPITER participants had
SCORE risk ≥5% using the extrapolated model compared with 35%
using the capped model. Analyses for patients with SCORE risk
,5% are included as Supplemental data.
Analyses were performed on an intention-to-treat basis. Hazard
ratios (HR) and 95% conﬁdence intervals (CI) were calculated from
the Cox proportional hazard models. Changes in lipoproteins and hs
C-reactive protein levels were compared by the Wilcoxon signed-rank
test. Baseline hs C-reactive protein is the mean of each participant’s
values at the screening and randomization visits. Analyses were per-
formed using SAS version 8.2 (SAS Institute, Inc., Cary, NC, USA).
Results
JUPITER enrolled 17 802 men and women (6515 in Europe), and
randomized 8901 each to rosuvastatin 20 mg daily and placebo.
At baseline, 9% of the cohort was considered to be at ‘high risk’
for a ﬁrst cardiovascular event on the basis of having a 10-year
Framingham risk of MI/coronary death above 20%; 52% were con-
sidered to be at ‘high risk’ on the basis of having a 10-year SCORE
risk of cardiovascular death of 5% or higher using the extrapolated
model, and 35% were considered to be at ‘high risk’ using the
W. Koenig and P.M Ridker 76capped SCORE model. Baseline characteristics of these high-risk
patients are shown by treatment allocation (Table 1). As antici-
pated, when compared with the entire JUPITER cohort, the
higher-risk patients were older, more often male and more likely
to smoke, have hypertension and low levels of HDL-C. Differences
between the high-risk Framingham and SCORE groups reﬂect the
patient characteristics included in the risk algorithms and their
weighted contribution to individuals’ estimated global cardiovascu-
lar risk. In particular, metabolic syndrome was more prevalent
among high-risk Framingham patients.
For the entire JUPITER cohort, rosuvastatin lowered LDL-C
by 50%, triglycerides by 17% and hs C-reactive protein by
37%, whereas it increased HDL-C by 4% compared with placebo
(P , 0.001 for all from baseline to year 1).
1 In the high-risk
groups, effects of rosuvastatin on lipoproteins and hs C-reactive
protein were similar to those seen for the entire cohort
(Table 2), with signiﬁcant reductions in LDL-C, triglycerides, and
hs C-reactive protein (P , 0.0001 vs. placebo for all) and a
signiﬁcant increase in HDL-C (P , 0.0001).
At study closure (median follow-up 1.8 years; maximal follow-up
5 years), the occurrence of MI/stroke/cardiovascular death was
lower among high-risk subjects allocated to rosuvastatin compared
with placebo (HR: 0.50, 95% CI: 0.27–0.93 for Framingham risk
score .20%; HR: 0.57, 95% CI: 0.43–0.78 for SCORE risk ≥5%
extrapolated model; HR: 0.47, 95% CI: 0.32–0.68 for SCORE risk
≥5% capped model; Figure 1, Table 3). The proportional reduction
in MI/stroke/cardiovascular death with rosuvastatin was similar for
patients with Framingham risk score above or below 20% (P for
interaction ¼ 0.95), or SCORE risk above or below 5% (P for
interaction ¼ 0.37 capped model, 0.25 extrapolated model).
Rosuvastatin signiﬁcantly reduced the occurrence of the primary
composite endpoint of MI/stroke/arterial revascularization/
unstable angina/cardiovascular death as well as fatal/non-fatal MI
and fatal/non-fatal stroke among patients with SCORE ≥5% (in
both the extrapolated and capped models; Table 3, Figure 2) and
reduced all-cause mortality in the capped SCORE model (Table 3).
In the higher-risk patients, there was no evidence of heterogen-
eity for the endpoint of MI/stroke/cardiovascular death in sub-
groups by gender, age, race/ethnicity, hypertension, smoking,
family history of premature coronary heart disease, baseline
HDL-C, or C-reactive protein (Figure 3). Patients with body mass
index .30 kg/m
2 at baseline appeared to beneﬁt less from rosu-
vastatin treatment compared with non-obese patients, but this
interaction between treatment assignment and body mass index
was not observed for the JUPITER cohort as a whole and thus is
likely to be more apparent than real.
In the high-risk patients, serious adverse events were reported
with similar frequency in rosuvastatin and placebo-allocated
patients (Table 4). A small excess of myalgia was reported with
rosuvastatin in patients with Framingham risk score .20%
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Table 1 Baseline characteristics according to the estimated 10-year risk deﬁned by the Framingham risk score or the
systematic coronary risk evaluation risk algorithm
Entire cohort Framingham 10-year
risk >20%
SCORE 10-year risk ≥5%
Extrapolated model Capped model
Rosuvastatin Placebo Rosuvastatin Placebo Rosuvastatin Placebo
n 17 802 786 772 4619 4683 3130 3177
Age (years) 66 74 74 70 70 67 67
Female (%) 38 17 15 32 31 12 11
Race or ethnic group (%)
White 71 68 67 72 72 74 74
Black 13 15 14 14 14 14 14
Hispanic 13 14 17 10 10 7 7
Other 4 2 2 2 3 4 4
Hypertension (%) 57 87 86 67 67 69 68
Current smoker (%) 16 32 31 21 22 30 31
Family history premature CHD
a (%) 12 8 11 10 10 10 10
HDL-C , 1.0 mmol/L (%) 23 60 60 22 22 24 24
Body mass index (kg/m
2) 2 8 2 82 8 2 82 8 2 82 8
Metabolic syndrome
b (%) 41 68 69 41 41 40 40
Framingham 10-year risk score 10 25 25 16 16 16 16
SCORE 10-year risk 5 14 14 9 9 10 10
Values are median or n (%). SCORE, systematic coronary risk evaluation; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol.
aCHD in a male ﬁrst-degree relative before age 55 or in a female ﬁrst-degree relative before age 65.
bMetabolic syndrome deﬁned as three or more of the following: waist circumference .102 cm (men) and 89 cm (women); triglycerides ≥1.7 mmol/L; HDL-C , 1.0 mmol/L
(men) and 1.3 mmol/L (women); blood pressure ≥85 mmHg diastolic or 130 mmHg systolic or treated hypertension; fasting glucose ≥5.6 mmol/L.
Rosuvastatin in high-risk patients 77(rosuvastatin 5.9% and placebo 5.3%) or SCORE risk ≥5% (rosu-
vastatin 7.9%, placebo 6.5% for the extrapolated model; 7.4 vs.
5.8% for the capped model). Myopathy, myositis, and rhabdomyo-
lysis were reported with similar frequency in the two treatment
groups. In the entire JUPITER cohort, investigator-reported dia-
betes, a non-adjudicated outcome, was more frequent with rosu-
vastatin (rosuvastatin 3.0% and placebo 2.4%; P ¼ 0.01).
1
Investigator-reported diabetes was not consistently more frequent
with rosuvastatin in the higher-risk patients (HR: 0.70, 95% CI:
0.41–1.19, P ¼ 0.19 for Framingham risk score .20%; HR: 1.11,
95% CI: 0.86–1.43, P ¼ 0.43 for extrapolated SCORE risk ≥5%;
HR: 0.99, 95% CI: 0.72–1.36, P ¼ 0.95 for capped SCORE risk).
At 2 years following randomization, a 0.1% greater increase in gly-
cosylated haemoglobin was observed with rosuvastatin compared
with placebo (P , 0.001 vs. placebo for the high-risk groups).
However, on-treatment fasting glucose levels were similar in the
two treatment groups (P ¼ 0.95 vs. placebo for Framingham risk
score .20%; P ¼ 0.19 for extrapolated SCORE risk ≥5%; P ¼
0.52 for the capped SCORE model).
Discussion
JUPITER investigated the effect of rosuvastatin 20 mg daily com-
pared with placebo on major cardiovascular events in a population
not requiring treatment under guidelines in effect in 2003,
9,11 but
at an increased cardiovascular risk on the basis of age and elevated
hs C-reactive protein. To provide European practitioners access to
post hoc subgroup data that were inﬂuential to the European health
authorities, in this analysis, we limited the target population to
select an even higher risk group using two global risk assessment
algorithms, Framingham and SCORE. In these higher risk sub-
groups, rosuvastatin lowered LDL-C, triglycerides, and hs
C-reactive protein and raised HDL-C, consistent with effects
observed for the entire cohort. Rosuvastatin reduced the risk of
the composite endpoint of MI/stroke/cardiovascular death by
50% in the high-risk Framingham group (P ¼ 0.028 vs. placebo),
43% in the high-risk SCORE group using the extrapolated model
(P ¼ 0.0003) and 53% (P , 0.0001) using the capped model, con-
sistent with the 47% reduction observed for the entire cohort.
1
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Table 2 Lipoprotein and high-sensitivity C-reactive protein levels in high-risk subgroups
SCORE 10-year risk ≥5%
Framingham 10-year risk >20% Extrapolated model Capped model
Rosuvastatin Placebo Rosuvastatin Placebo Rosuvastatin Placebo
LDL-C (mmol/L)
Baseline 2.8 (2.5–3.1) 2.8 (2.5–3.1) 2.8 (2.5–3.1) 2.8 (2.5–3.1) 2.8 (2.5–3.1) 2.8 (2.5–3.1)
Year 1 1.3 (1.1–1.9) 2.8 (2.4–3.2) 1.4 (1.1–1.8) 2.8 (2.4–3.2) 1.4 (1.1–1.9) 2.8 (2.4–3.2)
% change 251 0 249 +2 249 +2
P-value ,0.0001 ,0.0001 ,0.0001
Non-HDL-C (mmol/L)
Baseline 3.7 (3.3–4.0) 3.7 (3.3–4.0) 3.5 (3.1–3.87) 3.5 (3.1–3.8) 3.5 (3.1–3.8) 3.5 (3.1–3.8)
Year 1 2.0 (1.7–2.6) 3.6 (3.2–4.1) 2.0 (1.6–2.5) 3.5 (3.0–4.0) 2.0 (1.7–2.5) 3.5 (3.0–4.0)
% change 245 0 243 +2 242 +2
P-value ,0.0001 ,0.0001 ,0.0001
HDL-C (mmol/L )
Baseline 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.2 (1.0–1.5) 1.2 (1.0–1.5)
Year 1 1.1 (1.0–1.3) 1.0 (0.9–1.2) 1.3 (1.1–1.7) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.3 (1.0–1.6)
% change +9 +3 +60 +60
P-value ,0.0001 ,0.0001 ,0.0001
Triglycerides (mmol/L)
Baseline 1.7 (1.3–2.5) 1.7 (1.2–2.5) 1.3 (0.9–1.9) 1.3 (0.9–1.9) 1.3 (0.9–1.9) 1.3 (0.9–1.9)
Year 1 1.3 (1.0–1.8) 1.6 (1.2–2.4) 1.1 (0.8–1.5) 1.3 (1.0–1.8) 1.1 (0.8–1.6) 1.3 (1.0–1.9)
% change 222 23 216 0 216 +1
P-value ,0.0001 ,0.0001 ,0.0001
hs C-reactive protein (mg/L)
Baseline 4.6 (3.0–7.9) 4.6 (3.1–7.8) 4.2 (2.9–7.1) 4.4 (2.9–7.3) 4.2 (2.8–6.9) 4.4 (2.9–7.2)
Year 1 2.5 (1.3–4.8) 3.7 (2.3–6.7) 2.3 (1.3–4.6) 3.6 (2.0–6.4) 2.2 (1.2–4.5) 3.5 (2.0–6.4)
% change 249 217 246 221 246 221
P-value ,0.0001 ,0.0001 ,0.0001
Values are median (interquartile range) or median (%); SCORE, systematic coronary risk evaluation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; hs, high sensitivity.
W. Koenig and P.M Ridker 78Figure 1 Cumulative incidence of myocardial infarction/stroke/cardiovascular death in high-risk patients. The cumulative incidence of
myocardial infarction/stroke/cardiovascular death is shown by the treatment group for patients with a 10-year Framingham risk score
.20% (upper panel), 10-year systematic coronary risk evaluation risk ≥5% using the extrapolated model (middle panel), and systematic cor-
onary risk evaluation risk ≥5% using the capped model (lower panel). NNT, number needed to treat.
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Table 3 Major cardiovascular events and all-cause mortality in high-risk subgroups
Rosuvastatin Placebo ARR HR (95% CI) P-value
No. events Event rate
a No. events Event rate
Entire JUPITER cohort (n ¼ 8901 rosuvastatin, 8901 placebo)
Primary endpoint 142 7.7 251 13.6 5.9 0.56 (0.46–0.69) ,0.0001
MI/stroke/CV death 83 4.5 157 8.5 4.0 0.53 (0.40–0.69) ,0.0001
Total mortality 198 10.0 247 12.5 2.5 0.80 (0.67–0.97) 0.02
Baseline Framingham .20% (n ¼ 786 rosuvastatin, 772 placebo)
Primary endpoint 29 17.2 38 24.1 6.9 0.70 (0.43–1.14) 0.155
MI/stroke/CV death 16 9.4 29 18.2 8.8 0.50 (0.27–0.93) 0.028
Total mortality 31 17.2 40 23.6 6.3 0.73 (0.46–1.17) 0.193
Baseline SCORE ≥5% (extrapolated model; n ¼ 4619 rosuvastatin, 4683 placebo)
Primary endpoint 111 11.5 183 18.8 7.3 0.61 (0.48–0.78) ,0.0001
MI/stroke/CV death 67 6.9 118 12.0 5.1 0.57 (0.43–0.78) 0.0003
Total mortality 149 14.4 185 17.5 3.2 0.82 (0.66–1.02) 0.076
Baseline SCORE ≥5% (age capped at 65 years; n ¼ 3130 rosuvastatin, 3177 placebo)
Primary endpoint 71 11.1 130 20.1 9.0 0.56 (0.42–0.74) ,0.0001
MI/stroke/CV death 38 5.9 83 12.7 6.9 0.47 (0.32–0.68) ,0.0001
Total mortality 97 15 135 20.6 5.6 0.74 (0.57–0.96) 0.022
MI, myocardial infarction; CV, cardiovascular; HR, hazard ratio; CI, conﬁdence interval; SCORE, systematic coronary risk evaluation; ARR, absolute rate reduction. Primary
endpoint, time to occurrence of ﬁrst MI/stroke/cardiovascular death/arterial revascularization/unstable angina.
Data for the entire JUPITER cohort are from reference 1. Extrapolated and capped SCORE models are described in the ‘Methods’ section.
aRates are per 1000 person-years.
Figure 2 Cumulative incidence of fatal/non-fatal myocardial infarction and stroke in high-risk patients. The cumulative incidence of fatal/non-
fatal myocardial infarction and fatal/non-fatal stroke are shown by the treatment group among patients with a 10-year systematic coronary risk
evaluation risk ≥5% using the extrapolated (upper panel) and capped models (lower panel).
W. Koenig and P.M Ridker 80Figure 3 Effects of rosuvastatin on myocardial infarction/stroke/cardiovascular death in high-risk patients, according to baseline characteristics. The hazard ratios and 95% conﬁdence intervals
for rosuvastatin when compared with placebo are shown for patients with Framingham risk score .20% and systematic coronary risk evaluation risk ≥5% (extrapolated and capped models). Size
of the point estimate rectangle is proportional to the number of clinical events. The dashed vertical line indicates the relative risk reduction for the entire trial cohort. Also shown are P-values for
the test of an interaction between the composite endpoint and categories within each subgroup.
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1Adverse events and laboratory abnormalities were consistent with
the known safety proﬁle of rosuvastatin.
12
Strengths of this analysis include the randomized, placebo-
controlled design, broad geographic representation including a
substantial number of Europeans, and inclusion of large numbers
of women and ethnic minority participants. A limitation is the
post hoc selection of the higher risk subgroups, which was under-
taken in response to health authority requests.
4 For example,
analysis of JUPITER subgroups by SCORE strata was not pre-
speciﬁed and since SCORE by design is limited to those under
age 65, we needed to extrapolate ﬁndings for the many JUPITER
participants over this age cut-off that clearly beneﬁted from rosu-
vastatin.
13 The subgroups by baseline characteristics in Figure 3 are
drawn from within the subgroups of high-risk patients; as such,
limited conclusions can be drawn from these data. Neither the Fra-
mingham nor the SCORE models include hs C-reactive protein
evaluation; as all participants in JUPITER had hs C-reactive
protein levels .2 mg/L and as elevated hs C-reactive protein has
been shown to have a magnitude of risk prediction at least as
large as that of elevated cholesterol,
14 it is likely that both the Fra-
mingham and the SCORE systematically underestimate the true
risk of JUPITER participants.
Also in keeping with health authority requests, the analyses here
used a composite endpoint of MI/stroke/cardiovascular death
rather than the pre-speciﬁed JUPITER primary endpoint. Nonethe-
less, the relative reduction in MI/stroke/cardiovascular death with
rosuvastatin was remarkably consistent across a range of baseline
participant characteristics and consistent with primary trial ana-
lyses of the full study population as pre-speciﬁed in the JUPITER
protocol. Global risk prediction scores can be used to direct use
of preventive therapies such as statins towards patients most
likely to beneﬁt.
15,16 As expected, clinical event rates in the
JUPITER placebo group were higher in the high-risk Framingham
or SCORE groups compared with the entire cohort for the
primary study endpoint as well as for the composite of MI/
stroke/cardiovascular death and all-cause mortality. The magnitude
of the absolute rate reduction for clinical events was correspond-
ingly greater in the high-risk groups (Table 3).
Two factors contributing to the observed absolute reduction in
clinical events in JUPITER were the underlying event rate in the
placebo group, enhanced in this case by selecting patients with
high global cardiovascular risk and elevated hs C-reactive
protein, and the relative risk reduction due to treatment, enhanced
by use of a high-efﬁcacy statin. The reductions in LDL-C (49%) and
clinical events (43–53% for MI/stroke/cardiovascular death) with
rosuvastatin in the JUPITER patients with SCORE risk ≥5% are
greater than reported for other statins.
17,18 Although these data
support the use of high-efﬁcacy statin therapy, they do not
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Table 4 Adverse events and laboratory abnormalities in high-risk subgroups
Framingham risk >20% SCORE risk ≥5%
RSV Placebo Extrapolated model Capped model
RSV Placebo RSV Placebo
n 786 772 4619 4683 3130 3177
Any adverse event 626 (79.6) 617 (79.9) 3681 (79.7) 3704 (79.1) 2490 (79.6) 2510 (79.0)
Any serious adverse event 154 (19.6) 153 (19.8) 855 (18.5) 878 (18.7) 544 (17.4) 587 (18.5)
Muscle symptoms
Myalgia 46 (5.9) 41 (5.3) 363 (7.9) 303 (6.5) 233 (7.4) 183 (5.8)
Myositis 0 1 (0.1) 3 (0.1) 3 (0.1) 3 (0.1) 2 (0.1)
Myopathy 0 0 0 1 (0) 0 1 (0)
Rhabdomyolysis 0 0 1 (0) 0 1 (0) 0
Newly diagnosed cancer 35 (4.5) 39 (5.1) 195 (4.2) 212 (4.5) 116 (3.7) 145 (4.6)
Death from cancer 9 (1.1) 11 (1.4) 29 (0.6) 48 (1.0) 19 (0.6) 40 (1.3)
Gastrointestinal disorder 206 (26.2) 214 (27.7) 1184 (25.6) 1175 (25.1) 763 (24.4) 737 (23.2)
Renal disorder 100 (12.7) 87 (11.3) 487 (10.5) 523 (11.2) 355 (11.3) 354 (11.1)
Hepatic disorder 19 (2.4) 14 (1.8) 103 (2.2) 101 (2.2) 65 (2.1) 57 (1.8)
Investigator-reported diabetes 24 (3.1) 34 (4.4) 131 (2.8) 116 (2.5) 84 (2.7) 83 (2.6)
Laboratory values
Creatinine .100% increase from baseline [n (%)] 1 (0.1) 0 7 (0.2) 3 (0.1) 6 (0.2) 2 (0.1)
eGFR at 12 months (mL/min/1.73 m
2 ) 65.0 (14.2) 64.4 (13.9) 66.9 (14.2) 66.4 (13.6) 69.2 (14.3) 68.7 (13.3)
ALT.3x ULN on consecutive visits [n (%)] 3 (0.4) 2 (0.3) 14 (0.3) 6 (0.1) 12 (0.4) 5 (0.2)
HbA1c at 24 months (%) 6.02 (0.53) 5.92 (0.53) 5.96 (0.49) 5.86 (0.46) 5.97 (0.48) 5.87 (0.46)
Fasting glucose at 24 months (mmol/L) 5.7 (0.9) 5.7 (1.3) 5.6 (1.1) 5.6 (0.9) 5.6 (1.0) 5.6 (0.9)
Values are n (%) or mean (standard deviation). SCORE, systematic coronary risk evaluation; RSV, Rosuvastatin; eGFR, estimated glomerular ﬁltration rate; ALT, alanine
aminotransferase; HbA1c, glycosylated haemoglobin; ULN, upper limit of normal.
W. Koenig and P.M Ridker 82minimize the roles of diet, exercise, and smoking cessation as the
most important interventions for primary prevention. Despite the
beneﬁt derived from treatment with rosuvastatin in these high-risk
patients, caution should be exercised when considering treatment
of patients lacking any cardiovascular risk factors. Further, long-
term compliance with statin therapy is critical for efﬁcacy among
those patients where pharmacologic therapy is indicated in
addition to lifestyle interventions.
Although the analyses presented here parallel those requested
by European Health Authorities, they do not address most patients
actually studied in the JUPITER trial. For example, among the 7340
men and women with elevated hs C-reactive protein and the Fra-
mingham risk scores of 11–20%, where the 4.5-year absolute risk
of a primary endpoint was 10.6% in the placebo group, rosuvastatin
was associated with a 49% reduction in risk (HR: 0.51, 95% CI:
0.39–0.68, P , 0.0001). Similarly, among the 6091 participants
with entry Framingham scores of 5–10%, where the 4.5-year
absolute risk was 5.3%, a 45% reduction was observed with rosu-
vastatin (HR: 0.55, 95% CI: 0.36–0.84, P ¼ 0.005), and among trial
participants with elevated hs C-reactive protein with SCORE risk
,5%, rosuvastatin was associated with a 56% reduction in vascular
risk (HR: 0.44, 95% CI: 0.29–0.68). Thus, the JUPITER trial data
also indicate that many individuals with elevated hs C-reactive
protein who fall outside ‘high-risk’ subgroups deﬁned by either Fra-
mingham or SCORE have both substantive absolute risk and large
relative risk reductions when treated with rosuvastatin.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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